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perioperative, and mid-term outcome. J Card Surg. 2006;21:379-85.MMENTARYDo stentless valves make a difference?John Pepper, MDIn the early 1960s, Ross and Barratt-Boyes separately intro-
duced the aortic homograft into clinical practice. In 1965,
Binet and colleagues1 introduced a stentless porcine bio-
prosthesis, but this was not pursued because of difficulties
with implantation at a time when myocardial protection
was in its infancy. Stented bioprostheses were therefore
developed because their placement required a much simpler
technique and resulted in a reproducible performance.
Nevertheless, the transvalvular gradients and limited dura-
bility became major concerns. The original free-sewn
homograft circumvents most of these problems, but its
limited availability prevents its widespread use. Thisdiovascular Surgery c Volume 148, Number 5 1911
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Dlimitation eventually prompted the reconsideration of a
stentless design, intended to reduce residual obstruction of
transaortic flow by maximizing the available cross-
sectional area. The removal of the stent brought several ad-
vantages: (1) a larger valve can be implanted into a given
size of aortic annulus, (2) the distensibility and dynamic na-
ture of the aortic annulus is preserved,2 and (3) it is possible
to remodel the native aortic root and preserve the sinotubu-
lar junction.
A number of randomized trials have been undertaken to
compare stentless with stented valves in the aortic position.
Although the effective orifice area of stentless valves is
greater and the transvalvular gradients are lower, there is
no significant difference in the resolution of left ventricular
hypertrophy, as determined by left ventricular mass.3 It may
well be that this is too crude a measurement, and that
another instrument such as peripheral blood brain natri-
uretic peptide or a microRNA signature will be required
to show a difference. In the real world of everyday cardiac
surgery, however, it has not been possible to show a signif-
icant advantage of the stentless porcine valve. A large
meta-analysis4 that examined 17 randomized, controlled
trials involving 1317 patients concluded that despite the
improved hemodynamics, there had been no impact on
patient morbidity, mortality, or resource-related outcomes.
The article by Amabile and colleagues5 in this issue of the
Journal is a cohort study that is based on prospectively
collected data. Amabile and colleagues5 report on 500
patients who received a Freestyle valve (Medtronic, Inc,
Minneapolis, Minn) in a subcoronary configuration in the
majority (479/500). This is one of the largest series
reported. The survivals from cardiovascular mortality was
67% for all ages and 83% for patients younger than 65
years. The freedoms from structural valve disease at 10 years
were 94% overall and 89% for those younger than 65 years.
It is frustrating that we do not have longer follow-up,
because the hinge point for the onset of clinically significant
structural valve disease is generally around the 12-year
mark. It was hoped that the absence of a stent would enhance
the durability of a stentless valve, but there is no evidence to
support this so far. Amabile and colleagues5 regret that there
are no hemodynamic data, as their patients did not undergo a
protocol-led echocardiographic assessment. Nevertheless,
these results at 10 years are definitely acceptable.
So what is the indication for the use of a stentless porcine
valve in 2014? In the presence of infective endocarditis, it is a
reasonable alternative to a homograft to limit the amount of
foreign, man-made material.6 In reoperative aortic surgery,
when a root replacement is required, a stentless valve is often
an excellent choice of valve substitute. Smith and col-
leagues7 have used the Freestyle aortic root prosthesis in
the setting of acute aortic dissection. During a 4-year period,
24 of 80 patients received a root replacement with the1912 The Journal of Thoracic and Cardiovascular SurFreestyle valve. The operative mortality was 25%, and the
5-year survival was 62.5%. During this follow-up period,
no patients required reoperative aortic root replacement.
In the Ross operation, where a satisfactory pulmonary
homograft may not be available, a Freestyle valve and root
is a reasonable alternative provided a large size is chosen.
But Hechadi and colleagues8 sound a word of warning.
They used computed tomographic scanning to examine
calcification in pulmonary homografts and stentless valves
in the right ventricular outflow tract 2 years after the initial
operation. They found that calcification occurred in both
valve substitutes but progressed more rapidly in the porcine
stentless valve. They suggested that the Freestyle valve is
an acceptable alternative when a pulmonary homograft is
not available.
For a patient wishing to have a hemodynamically supe-
rior bioprosthetic valve substitute, the stentless porcine
valve is an excellent solution but valve durability is likely
to be very similar to that of a stented valve. Reoperative
root replacement can be a major undertaking, but valve-
in-valve is possible in a stentless porcine valve larger than
25 mm and is associated with a lower 30-day mortality
(3% vs 11%).9 In the current era of transcutaneous aortic
valve replacement, however, the Freestyle valve is very
suitable for a transcutaneous implant when the valve fails.10
This can be an attractive option for the patient who wishes
to avoid the problems of long-term anticoagulation.References
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